Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations

Opinion
Video

Vinay Raja, MD, explores the management of patients with Stage-III disease and actionable EGFR/ALK aberrations, as well as the treatment approach for patients with PD-L1 <1%.

CN_KC_SS_Seg09
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Content